The investigational PET tracer iodine-124 (I-124) evuzamitide met its primary endpoints for the diagnosis of cardiac amyloidosis, including transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to a recent press release.
The radiotracer showed effective sensitivity and specificity based on visual scan interpretation of positron emission tomography/computed tomography (PET/CT) imaging in patients with suspected cardiac amyloidosis.
“These I-124 evuzamitide data demonstrate the potential of a single test to help healthcare providers identify or exclude cardiac amyloidosis. Clinically, a sensitive, specific, and quantitative PET tracer could help distinguish cardiac amyloidosis from other causes of heart failure, differentiate amyloid subtypes when used alongside appropriate laboratory testing, and track changes in cardiac amyloid burden over time,” REVEAL principal investigator Dr. Sharmila Dorbala, director of nuclear cardiology at Brigham and Women’s Hospital, said in the release.